Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BAYER (BAY.TI)

TLO - TLO Delayed Price. Currency in EUR
Add to watchlist
49.55-1.93 (-3.75%)
At close: 05:15PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close51.48
Open50.84
Bid0.00 x 40000
Ask0.00 x 40000
Day's Range49.52 - 50.84
52 Week Range49.52 - 50.84
Volume789
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters

    EXPLAINER-Biotech corn and soy widely used, consumers still wary of GM wheat

    Nearly all corn and soybean acres in the world's largest exporting countries are seeded with genetically modified varieties, but that is not the case for wheat, a crop grown primarily for human food. Biotech varieties of corn and soy, used for animal feed, biofuels and ingredients like cooking oil, were introduced in 1996 and soon came to dominate plantings in the United States as well as Brazil and Argentina, the world's top suppliers. But genetically modified wheat has never been grown for commercial purposes due to consumer fears that allergens or toxicities could emerge in a staple used worldwide for bread, pasta and pastries.

  • Zacks

    Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

    The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.

  • Benzinga

    After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report

    Bayer AG (OTC: BAYRY) has started a hunt for CEO Werner Baumann's successor, Bloomberg News reported, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn't set to expire until April 2024. Bayer's chairman Norbert Winkeljohann is looking at prospects inside and outside the company to advance a new CEO candidate in time for Bayer's next shareholder meeting in April 2023, Bloomberg reports. Also Read: Bayer's Kidney Disease

Advertisement
Advertisement